DYN Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
181.7M
+45.0%
125.3M
+7.9%
116.1M
+2.0%
113.9M
-1.6%
115.8M
R&D
152.2M
+50.8%
100.9M
+5.7%
95.4M
-1.8%
97.2M
-2.0%
99.2M
SG&A
29.5M
+20.9%
24.4M
+17.8%
20.7M
+24.1%
16.7M
+0.7%
16.6M
Operating Income
-181661000
-45.0%
-125276000
-7.9%
-116129000
-2.0%
-113892000
+1.6%
-115791000
EBITDA
-181101000
-45.2%
-124726000
-7.9%
-115608000
-2.0%
-113369000
+1.7%
-115288000
Net Income
-178556000
-47.7%
-120854000
-7.9%
-111955000
-3.6%
-108041000
+2.5%
-110857000
EPS (Basic)
$-1.08
-47.9%
$-0.73
+3.9%
$-0.76
+0.0%
$-0.76
+21.6%
$-0.97
EPS (Diluted)
$-1.08
-47.9%
$-0.73
+3.9%
$-0.76
+0.0%
$-0.76
+21.6%
$-0.97
Shares (Diluted)
165.5M
+0.3%
165.0M
+11.4%
148.2M
+4.5%
141.8M
+24.5%
113.9M
Dyne Therapeutics (DYN) โ€” Financials